The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Postural Instability and Gait Disturbances, 2009Relationship between REM Behavior Disorder and Freezing of Gait in Parkinson's Disease
Objective/Rationale:
Many people with REM sleep behavior disorder (RBD), a disease associated with disturbance of sleep, eventually develop Parkinson’s disease. Dysfunction and degeneration of... -
Postural Instability and Gait Disturbances, 2009Determining the Neural Correlates of Freezing of Gait in Parkinson's Disease Using Functional Magnetic Resonance Imaging
Objective/Rationale:
Freezing of Gait (FOG) in Parkinson’s disease occurs when a person’s feet become suddenly ‘frozen’ while walking or turning. FOG is a leading cause of falls, and responds poorly to... -
MJFF Research Grant, 2009Pilot Assessment of the Effect of Optimism and Expectation on Dyskinesia Rating Scales in Parkinson's Disease Subjects Randomized to Placebo or Amantadine
Objective/Rationale:
The effects of placebo response in clinical and surgical interventions in PD have become increasingly recognized. Many factors have been associated with placebo response including... -
Therapeutics Development Initiative, 2009IMD-026259 An Innovative Drug for Disease-Modifying Treatment of Parkinson´s Disease
Objective/Rationale:
Parkinson’s disease progresses through the death of brain cells caused by “oxidative stress.” This takes place in dysfunctional mitochondria - structures within each cell... -
Therapeutics Development Initiative, 2009Potential Efficacy of a Novel HDAC Inhibitor in Pre-clinical Models of Parkinson's Disease
Objective/Rationale:
Histone deacetylases (HDACs) are a family of enzymes that reduce gene expression and can regulate protein clearance. Inhibitors of HDACs have been reported to be efficacious in... -
Therapeutics Development Initiative, 2009Development of Anti-toll-like Receptor (TLR)-2 Monoclonal Antibody as a Therapeutic Agent in Parkinson's Disease
Objective/Rationale:
Parkinson’s is associated with an inflammatory response, which in the brain is mainly mediated by cells called microglia. Inflammation is normally beneficial helping us fight...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.